News

Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with Therapy Providers Can Access Patient-Specific Data for...

• Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in...

-aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization...

New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 – WALTHAM, MA...

First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021 – WALTHAM, MA – Scipher Medicine, a...

By: Rob Volansky If there was any question about whether rheumatologists would utilize an effective biomarker that can predict response...

Nine out of 10 responding rheumatologists stated the test would increase their confidence when making prescribing decisions WALTHAM, Mass. –...

Dr. Regina Benjamin to Advise on Access to Precision Medicine Driving Better Health Outcomes for Patients with Autoimmune Diseases OCTOBER...

PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory. Partnership provides infrastructure for rapid scaling and patient accessibility.

Scipher Medicine is a spin-out of Northeastern University founded on the basis of, first, building a map of human biology...